TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07452224: ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Sponsor: iLeukon Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07452224 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07452224 Rescue Dossier →